Back to top
more

Amedisys (AMED)

(Real Time Quote from BATS)

$100.76 USD

100.76
866,060

-0.19 (-0.19%)

Updated Aug 13, 2025 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amedisys (AMED) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 27.78% and 0.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Healthcare Stock Earnings Slated on Oct 29: HCA, MOH & More

by Zacks Equity Research

Increasing demands for products and services are likely to have driven earnings for players in the healthcare industry.

Zacks Equity Research

AMED vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMED vs. USPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Amedisys (AMED) Upgraded to Buy: Here's Why

by Zacks Equity Research

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sumit Singh headshot

Add These 5 Stocks With Amazing Interest Coverage Ratio

by Sumit Singh

Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.

Urmimala Biswas headshot

Medtronic Submits Two Pelvic Health Devices for FDA's PMA

by Urmimala Biswas

Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

Zacks Equity Research

Omnicell Advances on Global Footing Despite Severe Rivalry

by Zacks Equity Research

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Zacks Equity Research

Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

by Zacks Equity Research

Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

Zacks Equity Research

Illumina, Broad Institute Partner on Secondary Genomic Analysis

by Zacks Equity Research

The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

Zacks Equity Research

Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

by Zacks Equity Research

The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.

Zacks Equity Research

Haemonetics Grows on Strong Plasma, Hemostasis Management

by Zacks Equity Research

Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

Zacks Equity Research

Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high in GNC Holdings (GNC), thanks to solid prospects.

Zacks Equity Research

What Makes Amedisys (AMED) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.

Zacks Equity Research

Here's Why You Should Hold on to Wright Medical (WMGI) Stock

by Zacks Equity Research

Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.

Zacks Equity Research

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

by Zacks Equity Research

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Zacks Equity Research

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

by Zacks Equity Research

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

Zacks Equity Research

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Zacks Equity Research

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

by Zacks Equity Research

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Zacks Equity Research

PRA Health Simplifies Treatment Decisions With Metys Launch

by Zacks Equity Research

PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.

Zacks Equity Research

Here's Why You Should Retain Pacific Biosciences For Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.